Drug Delivery System
Online ISSN : 1881-2732
Print ISSN : 0913-5006
ISSN-L : 0913-5006
Search
Advanced search
OR
Browse
Search
Volume 37, Issue 5
Drug Delivery System
Displaying 1-14 of 14 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
FOREWORD
OPINION
  • Past, present and future of infectious diseases
    Yoshiharu Matsuura
    2022 Volume 37 Issue 5 Pages 372-376
    Published: November 25, 2022
    Released on J-STAGE: February 25, 2023
    DOIhttps://doi.org/10.2745/dds.37.372
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    The history of humankind has been a battle against infectious diseases, and highly lethal viral infections have appeared many times. Even in Japan, one-fourth of the population was lost due to smallpox during the Nara period. In the modern era, effective vaccines and drugs were developed, and everyone was optimistic that infectious diseases could be eradicated from the earth by the end of the 20th century. However, infectious diseases such as AIDS, influenza, SARS, and MERS emerged. In particular, the novel coronavirus pandemic that occurred in Wuhan, China, at the end of 2019 exposed the vulnerability of modern society to infectious diseases. Furthermore, infectious diseases are undergoing significant changes due to human factors such as globalization and the destruction of nature. In this review, I would like to outline the infectious diseases that humans have experienced so far and introduce the fight against the new coronavirus and future infectious disease countermeasures.
    View full abstract
    Download PDF (620K)
[Feature articles] “Application of DDS to vaccines and therapeutic antibodies against infectious diseases” Editor:Yasuo Yoshioka
  • Development of therapeutic antibodies for the treatment of infection diseases and future aspect
    Kenta Haraya, Keisuke Gotanda, Rie Shiokawa, Maiko Hoshino, Chiyomi Ku ...
    2022 Volume 37 Issue 5 Pages 378-387
    Published: November 25, 2022
    Released on J-STAGE: February 25, 2023
    DOIhttps://doi.org/10.2745/dds.37.378
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Since the late 1990s, therapeutic antibodies have been developed for various oncology and immunoinflammatory diseases. To date, more than 100 therapeutic antibodies have been approved in Japan, the U.S., and Europe for these indications. In contrast, the development of antibody drugs in the field of infectious diseases has been limited so far. The recent SARS-CoV-2 pandemic has highlighted the importance of therapeutic antibodies for infectious diseases as well as the development of drug delivery systems（DDS）. This review summarizes the past development of antibody drugs for infectious diseases and provides a future perspective of how therapeutic antibodies can be developed by utilizing antibody engineering and DDS technologies.
    View full abstract
    Download PDF (576K)
  • Development of broadly reactive antibody therapeutics for SARS-CoV-2
    Saya Moriyama
    2022 Volume 37 Issue 5 Pages 388-394
    Published: November 25, 2022
    Released on J-STAGE: February 25, 2023
    DOIhttps://doi.org/10.2745/dds.37.388
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Various antibody therapeutics has been developed for the treatment and suppression of the 2019 outbreak of novel coronavirus（SARS-CoV-2）infection. A major limitation in the development of SARS-CoV-2 neutralizing antibodies is the occurrence and spread of escape variants that have mutations in the spike glycoprotein. The coronaviruses are carried by various wild animals, domestic animals, and pets, and there have been cases of Severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus transmission from animals to people, resulting in a large spread of infection in people. There is also a possibility that cross-species transmission of SARS-CoV-2 may occur in the future. Considering these factors, the development of antibody therapeutics with broad cross-reactivity against SARS-CoV-2 variants and other coronaviruses is required.
    View full abstract
    Download PDF (434K)
  • Development of indigestible IgA antibody for restoring microbiome balance
    Reiko Shinkura
    2022 Volume 37 Issue 5 Pages 395-401
    Published: November 25, 2022
    Released on J-STAGE: February 25, 2023
    DOIhttps://doi.org/10.2745/dds.37.395
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Dysbiosis, especially in the gut plays a crucial role in the pathogenesis of a wide variety of diseases, including inflammatory bowel disease, colorectal cancer, cardiovascular disease, obesity, diabetes and multiple sclerosis. At mucosal surfaces, mucosal polymeric immunoglobulin A（IgA）antibodies are known to be important to regulate the gut microbiota as well as to exclude infection induced by pathogenic bacteria or virus such as influenza and SARS-CoV-2（severe acute respiratory syndrome coronavirus 2）. Since the 1970s, oral administration of IgA or IgG antibodies has been performed against infectious enteritis caused by pathogenic Escherichia coli or Clostridioides difficile. However, none of them has been successfully developed as an antibody drug up to now. Although IgA is well known to modulate the gut commensal microbiota, the therapeutic IgA drugs to treat dysbiosis has not been developed. Here, we discuss the advantages of therapeutic IgA antibodies.
    View full abstract
    Download PDF (739K)
  • Current Status and Prospects of Vaccines based on DDS Technology
    Atsushi Kawai, Toshiro Hirai, Yasushi Yoshioka
    2022 Volume 37 Issue 5 Pages 402-411
    Published: November 25, 2022
    Released on J-STAGE: February 25, 2023
    DOIhttps://doi.org/10.2745/dds.37.402
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    The development of DDS technology has contributed critically to the unprecedentedly rapid requirement for vaccines against COVID-19. LNP-based mRNA vaccines represent a subset of emerging DDS technology. Despite the groundbreaking nature of these vaccines, they are yet to be perfected and as such, new technologies are being developed to optimize these vaccines. This review will focus on exploring one of the modalities of recombinant protein vaccines and will introduce various findings on the enhancement of vaccine efficacy using antigen modification technologies, including VLPs and Fc-fusion proteins, and adjuvant improvements.
    View full abstract
    Download PDF (789K)
  • Development of mucosal vaccine based on DDS
    Koji Hosomi, Jun Kunisawa
    2022 Volume 37 Issue 5 Pages 412-420
    Published: November 25, 2022
    Released on J-STAGE: February 25, 2023
    DOIhttps://doi.org/10.2745/dds.37.412
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Mucosal vaccines, in which vaccination is administered through mucosal （e.g., oral and nasal） routes, are attracting attention. Applications of delivery system and adjuvant are prerequisite for the practical use of mucosal vaccines. Delivery systems based on polymers, nanogels, lipids, and microbial components can promote delivery efficacy and extend the retention of vaccine antigens into mucosal tissues, resulting in the enhanced vaccine efficacy. In addition to delivery functions, adjuvant functions that can control immune responses such as activation of antigen presenting cells and induction of appropriate T cell responses are required to develop more effective vaccines. Here, we would like to introduce the development of next-generation delivery systems that can impart appropriate functions to various vaccine targets.
    View full abstract
    Download PDF (594K)
  • Adenovirus vector vaccines
    Hiroyuki Mizuguchi, Masashi Tachibana, Fuminori Sakurai
    2022 Volume 37 Issue 5 Pages 421-428
    Published: November 25, 2022
    Released on J-STAGE: February 25, 2023
    DOIhttps://doi.org/10.2745/dds.37.421
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Recently, importance of vaccines for treatment and prevention of emerging and re-emerging infectious diseases has been re-recognized. A replication-incompetent adenovirus（Ad） vector vaccine expressing virus antigen proteins is one of the most advanced platforms as a novel vaccine because an Ad vector vaccine can be rapidly applicable to pandemic. In this review, we describe the basic properties of an Ad vector for vaccine, in addition to the summary of the development of an Ad vector vaccine for emerging and re-emerging infectious diseases, including Coronavirus disease 2019（COVID-19）, worldwide.
    View full abstract
    Download PDF (1687K)
  • Viral vector vaccines: efforts to develop vaccines against emerging infectious diseases
    Tokiko Watanabe
    2022 Volume 37 Issue 5 Pages 429-436
    Published: November 25, 2022
    Released on J-STAGE: February 25, 2023
    DOIhttps://doi.org/10.2745/dds.37.429
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Vaccines are one of the most effective means of preventing viral infections. Since Edward Jenner invented the world’s first vaccine in 1796, against smallpox, various types of vaccine have been developed, including inactivated vaccines, attenuated live vaccines, recombinant protein vaccines, viral vector vaccines and nucleic acid vaccines. Viral vector vaccines and nucleic acid vaccines （mRNA vaccines and DNA vaccines） have been developed most recently. In these vaccines, genes encoding viral proteins that serve as antigens are introduced into the body. The viral vector is an excellent vaccine delivery system that efficiently delivers antigen genes to target cells, and has been utilized for vaccine development against a variety of emerging infectious diseases, including AIDS, malaria, Ebola hemorrhagic fever, dengue fever, and most recently COVID-19. Here, we provide an overview of viral vector vaccines and discuss recent efforts to develop vaccines against emerging infectious diseases.
    View full abstract
    Download PDF (519K)
Front line of DDS development in pharmaceutical industries
  • Development of LONASENⓇTape, the world’s first transdermal antipsychotic drug
    Masayasu Tanaka
    2022 Volume 37 Issue 5 Pages 438-443
    Published: November 25, 2022
    Released on J-STAGE: February 25, 2023
    DOIhttps://doi.org/10.2745/dds.37.438
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Blonanserin is an atypical antipsychotic drug with dopamine D2, D3 and serotonin 5-HT2A receptor antagonism. We jointly developed the world’s first antipsychotic transdermal patch containing blonanserin as active pharmaceutical ingredient with Nitto Denko Corporation, and started domestic sales in September 2019. There are three technical hurdles in formulation development of transdermal patch： skin permeability, skin irritation, and adhesiveness. We overcame these technical hurdles and succeeded in developing the formulation of LONASENⓇ Tape. Here, along with detail report on the formulation development, the background to development and the results of clinical studies are also described.
    View full abstract
    Download PDF (488K)
Tips for your DDS research
“Young Square” (mini review)
Meeting Reports
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top